Freeze-Dried Peptides and a Perth Summer: What Studies Report on Heat, Light and Water

Why are research peptides supplied freeze-dried?

The literature review of peptide solid-form stabilisation by Zapadka et al. (Interface Focus, 2017) describes freeze drying as a common way to prepare solid peptides; it summarises published studies and tested no catalogue product. This site's home page and about page, read on 14 October 2026, describe the compounds as supplied freeze-dried.

Thiol-disulfide exchange is a reaction in which a molecule's sulfur bridges rearrange. In a laboratory study of peptides corresponding to tryptic fragments of human growth hormone, held as lyophilised powders at 22 °C and ambient relative humidity, thiol-disulfide exchange occurred in the solid state with reaction rates and product distribution that differed from those in aqueous solution; the study used fragment peptides and not finished products, and the abstract reports no sample size (Chandrasekhar and Topp, Journal of Pharmaceutical Sciences, 2015).

The two sources address different questions. The literature review summarises published work on solid-form stabilisation (Zapadka et al., 2017), and the laboratory study followed one reaction in fragment peptides (Chandrasekhar and Topp, 2015). Neither measured a product from this catalogue.

Evidence limits

What can no storage page tell you about a specific vial?

The 2015 audit by Verbeke et al. covered one peptide class and one set of 98 peptides, and it does not show how often certificate and test results differ elsewhere. A certificate of analysis reports on the lot it was issued for. What a batch or lot number lets a researcher verify sets out the chain from number to report, and the wider peptide quality and verification pages cover that machinery in full.

What do heat and light actually do to peptide material?

The studies cited here do not establish a heat or light rule for peptides as a class. In a six-month laboratory study of solid human insulin at 6 °C, 25 °C and 40 °C, deamidation and covalent aggregation were the main degradation pathways and their rates rose with temperature; the abstract gives no sample number, and the result covers one protein in one solid form, rather than any catalogue compound (Fagan et al., Journal of Pharmaceutical Sciences, 2025).

In a separate laboratory study, near-ultraviolet and visible light acting on citrate buffer with iron present induced cleavage of peptide and protein disulfide bonds; the abstract gives no sample number, and the result is for that solution system and not for a dry powder (Prajapati et al., Journal of Pharmaceutical Sciences, 2022).

Deamidation is the loss of an amide group from an amino acid side chain, and covalent aggregation is the bonding of molecules into larger clusters. The Bureau of Meteorology's climate statistics for Perth Metro (site 009225, mean maximum temperature over 32 years, 1994 to 2026) give a mean maximum air temperature of 29.6 °C in December, 31.4 °C in January and 31.7 °C in February, against an annual mean maximum of 24.9 °C (page prepared 9 October 2026, retrieved 14 October 2026). These are weather-station air temperatures. They say nothing about the temperature of any parcel or vial.

In a laboratory photostability study of the protein somatropin, light exposure altered quality attributes of the lyophilised, reconstituted and diluted forms, with more pronounced effects on the liquid forms; the abstract gives no sample numbers, and this single-protein experiment does not establish outcomes for catalogue peptides (Pritts et al., Pharmaceutical Research, 2026).

Why does water content matter in a dried powder?

The studies cited here do not set one water-content rule for dried peptides. In a laboratory thermal-stress study of solid semaglutide, thermal analysis detected residual water loss; the abstract gives no sample number, and the finding covers that one molecule under thermal stress (Akbar et al., Pharmaceutical Research, 2026).

A 2023 report on how peptide reference standards are produced and characterised, which uses case studies and not a survey of commercial lots, describes assigning a value to a bulk peptide by a mass balance approach: all species other than the native peptide, such as impurities and counter ions, are identified and measured, and tests for residual solvents, residue on ignition and moisture are part of the work (McCarthy et al., Pharmaceutical Research, 2023). Separately, a laboratory thermal-stress study of solid semaglutide only, with no sample number in the abstract, detected loss of residual water from the solid by thermal analysis (Akbar et al., 2026). Neither study measured a product from this catalogue.

Why are peptides stored in a refrigerator?

No source read for this page gives one reason that covers peptides as a class. Stability studies of single molecules compare material across temperatures. In a six-month laboratory study of solid human insulin, deamidation and covalent aggregation rates rose with temperature; the finding covers that one protein and the abstract gives no sample number (Fagan et al., Journal of Pharmaceutical Sciences, 2025). In a laboratory study of solid semaglutide under thermal stress, chromatography and mass spectrometry showed temperature-dependent degradation and impurity formation; the abstract gives no sample numbers, and the finding covers that one molecule under thermal stress (Akbar et al., Pharmaceutical Research, 2026).

Zapadka et al. (2017) discuss the limits of extrapolating aggregation measurements between temperatures in a literature review; they did not test catalogue products. The review appeared in Interface Focus.

What do WHO and ICH guidelines say about refrigerating peptides?

Neither guideline names a peptide. Both define the refrigerator and the freezer as stability-test conditions for medicines: 5 °C ± 3 °C for the refrigerator and -20 °C ± 5 °C for the freezer (ICH Q1A(R2), step 4 version dated 6 February 2003; WHO Technical Report Series 1010, Annex 10, 30 September 2018). Both are registration guidelines for medicines: they describe the stability data a maker supplies in support of a label statement. They are not studies of research material and do not examine any lot in this catalogue.

ICH Q1A(R2) states that it addresses registration applications for new molecular entities and associated drug products, and points to a separate guideline, Q5C, for biotechnological and biological products. For drug substances intended for storage in a refrigerator, section 2.1.7.2 sets a long-term study at 5 °C ± 3 °C with 12 months of data at submission, and an accelerated study at 25 °C ± 2 °C and 60% relative humidity ± 5% for 6 months. WHO's annex states that its guidance was first published as Annex 2 of Technical Report Series 953 (2009), and says it may generally apply to the stability testing of biologicals, with additional requirements in ICH Q5C. Its Appendix 2 table pairs the condition under which a finished product's stability was demonstrated with a label statement, and lists three such conditions: 5 °C ± 3 °C, -20 °C ± 5 °C, and 25 °C with 60% relative humidity, long-term. The refrigerator is one rung on a ladder of conditions.

Both texts describe how a maker supports a label statement for its own product. Neither sets one for research material.

What do FDA documents say about storing peptide medicines and compounded peptides?

The two FDA documents read for this page give storage statements product by product and not as one rule for peptides. The label for EGRIFTA SV (tesamorelin) on DailyMed (record updated 29 July 2026) has its own section 16, 'How supplied/storage and handling', which describes the product as a lyophilised powder in a single-dose vial. The Egrifta SV label contains product-specific storage information; this page does not reproduce those directions. The FDA's briefing document on BPC-157, dated 11 May 2026 and prepared for the 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting, reports storage statements for lyophilised and dissolved BPC-157 that cite two supplier web pages (footnotes 14 and 15, accessed 26 June 2024).

The briefing document's storage statements for BPC-157 rest on two supplier web pages and are not an FDA measurement of any product. The FDA briefing warns that formulation, manufacturing and environmental conditions can affect peptide stability; this warning cites a literature review rather than a product test (FDA, 11 May 2026; Zapadka et al., 2017).

The label statement applies to one approved product and the briefing document concerns one compound, so neither establishes storage conditions for a product or lot sold in this catalogue. This page makes no claim beyond those two documents.

Do sources place peptides in the refrigerator or the freezer?

Published sources name both bands, for different purposes. Stability guidelines define a refrigerator test condition of 5 °C ± 3 °C and a freezer test condition of -20 °C ± 5 °C (ICH Q1A(R2), 6 February 2003; WHO TRS 1010 Annex 10, 30 September 2018). The studies read for this page did not compare the two bands for the compounds in this catalogue, and this page does not rank one band above the other.

The freezer band carries its own evidence rule. For a drug product intended for a freezer, ICH Q1A(R2) section 2.2.7.5 says the shelf life 'should be based on the real time data obtained at the long term storage condition'. Where there is no accelerated condition for such a product, it says testing 'on a single batch at an elevated temperature (e.g., 5°C ± 3°C or 25°C ± 2°C) for an appropriate time period should be conducted to address the effect of short term excursions outside the proposed label storage condition'. A freezer condition is therefore a tested condition tied to a product's own data.

No single band is reported as best across the sources read. Lot-level information sits in the lab report, and how to read a certificate of analysis covers that paperwork.

Can a mini fridge store peptides?

No source read for this page says whether a mini fridge suits peptide material. The closest official Australian document, the Strive for 5 national vaccine storage guidelines (4th edition, Australian Government Department of Health, Disability and Ageing, September 2025), records a risk of vaccine freezing in domestic refrigerators, including bar fridges. It contains no peptide-specific finding, so it is a reference point and not a result for peptides, and the studies read measured no peptide material in a mini fridge.

The guidelines name freezing as the risk for vaccines in such fridges. No source read for this page names a model or brand of mini fridge, and this page names none.

What does this page deliberately not cover?

Transit. The sources read for this page did not state the conditions a parcel experiences on the road. This site's shipping page, read on 14 October 2026, gives dispatch carriers, delivery windows and packaging appearance, and no temperature or handling conditions, so this page claims none. That is the page's defined edge and not a gap: the journey belongs to the delivery pages, and Perth peptide delivery times by state covers delivery windows. Shelf life is the other absence: none is stated in the sources read, and the record for any batch is its own lab report.

The journey belongs to the delivery pages in the wider Perth peptides hub. What is documented here is the literature on freeze-dried material, dated and sourced.